-
2022-501361-44-00
5
Adult patients of either gender with active moderate to severe rheumat
-
2025-522471-28-00
5
psoriatic arthritis (PsA)
-
2025-522542-40-00
5
Acute Ischemic Stroke
-
2022-501890-38-00
4
2024-02-16
acute ischemic stroke
-
2022-500273-14-00
10
2023-07-17
Atherosclerotic cardiovascular disease in patients with ESKD
-
2022-501354-10-01
5
2023-06-21
axial spondyloarthritis
-
2025-523847-36-00
3
2026-05-19
Participants with Mild, Moderate, or Severe Hepatic Impairment and Par
-
2025-523123-22-00
5
2026-05-07
Chronic Kidney Disease
-
2025-521546-23-00
5
2026-04-21
Secondary progressive multiple sclerosis
-
2025-521416-19-00
4
2026-03-12
Recurrence of Clostridioides difficile Infection
-
2025-522960-34-00
5
2026-02-09
Established cardiovascular disease
-
2025-523695-23-00
3
2025-12-11
Not applicable (trial is a pharmacokinetic study in healthy volunteers
-
2024-517614-14-00
4
2025-11-28
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
-
2025-521947-19-00
3
2025-11-19
Healthy, Hepatic Insufficiency
-
2024-515979-35-00
5
2025-11-13
Generalized Myasthenia Gravis
-
2025-520754-11-00
3
2025-08-25
Parkinson's disease
-
2024-516337-12-00
5
2025-08-07
Knee osteoarthritis with moderate to severe pain
-
2024-519059-28-00
5
2025-07-17
Chronic Heart Failure
-
2023-507195-43-00
3
2024-07-01
Amyotrophic Lateral Sclerosis (ALS)
-
2023-503224-66-00
5
2023-10-31
Atrial Fibrillation
-
2025-521127-73-00
5
2025-09-12
Relapsing forms of Multiple Sclerosis
-
2024-520315-40-00
3
2025-07-22
Normal Hepatic Function and Mild, Moderate, or Severe Hepatic Impairme
-
2024-515907-20-00
9
2025-05-23
Primary biliary cholangitis (PBC)
-
2024-516213-20-00
5
2025-03-25
Psoriatic arthritis